Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Taiho Oncology, Inc.
The trial was put on Clinical Hold prior to Phase 2 due to cases of drug induced liver injury meeting the criteria for Hy's Law. Background and Rationale: • TAS4464 is an investigational NEDD8 activating enzyme (NAE) inhibitor, a compound which may affect cancer cell growth and survival. Thus, TAS4464 may help in the treatment of cancer. Phase 1: Primary: * To investigate the safety and tolerability of TAS4464 * To identify a tolerated dose of TAS4464 Secondary: * To investigate the preliminary efficacy of TAS4464 * To investigate the pharmacokinetics (PK) and the pharmacogenomics (PGx) of TAS4464 * To investigate the pharmacodynamics of TAS4464
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted